SCHEDULE: MAK Capital Discloses 12.6% Stake in Autolus Therapeutics

Investment firm MAK Capital and Michael A. Kaufman have reported a 12.6% beneficial ownership stake in Autolus Therapeutics plc.

Summary

• MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman filed a Schedule 13G/A amendment.
• The reporting persons collectively hold 33,621,487 American Depositary Shares (ADS).
• This holding represents 12.6% of the total outstanding ordinary shares of Autolus Therapeutics plc.
• The calculation is based on 266,155,786 shares outstanding as of May 13, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-positive development, as it reflects stable institutional backing without indicating an activist campaign for control.

Positives

• Significant institutional investment indicates long-term confidence in the company's pipeline and market position.
• The filing confirms the reporting persons do not intend to change or influence the control of the issuer.

Negatives

• Large block ownership can lead to increased share price volatility if the holder decides to divest.

Risks

• Concentration of ownership may impact liquidity if the reporting persons decide to sell significant portions of their holdings.

Future Outlook

The reporting persons have certified that the securities were not acquired for the purpose of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that significant 13G filings in the biotech sector often signal institutional support for clinical-stage companies, providing a floor for valuation while potentially increasing volatility during exit events.

Comparison to Industry Standards

• The 12.6% stake is a substantial position, consistent with active institutional investment strategies in the small-to-mid-cap biotechnology space.
• The filing follows standard regulatory requirements for institutional investors exceeding the 5% ownership threshold.

Stakeholder Impact

• Shareholders may view the presence of a large institutional holder as a sign of stability.
• Potential for increased trading volume if the reporting persons adjust their position.

Next Steps

• Continued monitoring of future 13G/A filings for any changes in the reporting persons' ownership levels.

Key Dates

Keywords

Autolus Therapeutics, MAK Capital, Schedule 13G, Institutional Ownership, Biotech, ADS